HEPALIFE TO ACCELERATE RESEARCH ACTIVITIES AND BOLSTER MANAGEMENT AND RESEARCH TEAMS

HepaLife Technologies, Inc. today unveiled plans to accelerate its research and development activities for the first-of-its-kind artificial liver device based on the patented PICM-19 cell line, which thus far has demonstrated to be highly metabolic and ideally suited for incorporation into an artificial liver device. Recently, positive research findings related to the prolonged survival, density and function of HepaLife's cell line were presented at the annual National Biomedical Engineering Society Meeting.
Business Wire